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Abstract In Portugal, the spectrum of Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) gene variants is not known. The main objective of this work was to determine the type
and frequency of CFTR variants in a sample from northern Portugal by the complete analysis of
the CFTR coding sequencing performed in 512 Portuguese children. A total of 30 different CFTR
sequence variants, already reported as cystic fibrosis (CF) or CFTR related disorders variants,
were detected. Ninety-two children (18.0%; 95%CI: 14.7--21.6) were found to be carriers of
one sequence variant and 8 (1.6%; 95%CI: 0.7--3.1) had two sequence variants. Taking into
consideration only variants that may cause CF when combined with a pathogenic CF variant, the
CF pathogenic variant carrier frequency was 3.3% (95%CI: 1.9--5.3). One (0.2%; 95%CI: 0.01--0.7)
child presented two CF pathogenic variants.
Conclusions: The majority of CFTR variants detected have been associated with a less severe CF
phenotype. A wide spectrum of CFTR variants was identified, confirming the highest CFTR allelic
heterogeneity previously reported in Mediterranean country. Additionally, better knowledge
about the CFTR sequence variation spectrum may contribute to more efficient genetic testing
in the Portuguese population.
© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Abbreviations: CBAVD, congenital bilateral absence of the vas deferens; CFTR-RD, CFTR-related disorders; CI, confidence intervals;
NGS, next generation sequencing.
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ystic Fibrosis (CF, OMIM # 219700) is the most frequent
onogenic autosomal recessive disease in the Caucasian
opulation. The improvement in the health care of CF
atients in recent years has led to an increased survival,
eing the median predicted survival age of 50.5 (95%CI:
7.5--53.5).1
The incidence of CF in Europe has become well defined
n recent years due to the newborn screening programmes
nd the improvement in CF patient registries in different
uropean countries facilitating accurate assessment of CF
revalence in Europe.2,3
On average, 1 in 25--30 individuals is a carrier of
Cystic Fibrosis Transmembrane Conductance Regulator
CFTR) pathogenic variant and 1 in 2500--3500 newborns
re affected with CF, however there are significant varia-
ions according to ethnic group and geographical location.4,5
F prevalence in Portugal, based on the neonatal screening
nitiated in October 2013, is estimated to be 1:7500 (Ana
arcão, oral presentation, 2017).
Since the identification of the CFTR gene in 1989, more
han 2000 variants have been reported, with wide geograph-
cal variation.6--9 This gene encodes a CFTR protein, which
unctions as a chloride channel located in the apical mem-
rane of secretory epithelial cells.10
Pathogenic variants in the CFTR gene result in a vari-
ty of consequences associated with abnormal function of
pithelial and exocrine glands, leading to a multisystemic
isease.11
To date, p.Phe508del (F508del) is the most common
F-pathogenic variant, accounting for about 70% of all
athogenic variants in Caucasians.2,4,12 Besides p.Phe508del,
here are very few pathogenic variants with global frequen-
ies higher than 1%. While in Northern and Central Europe
here is a high degree of homogeneity of CFTR variants,
outhern European countries have a more heterogeneous
FTR spectrum.4,13
Seven CF-pathogenic variants, p.Arg334Trp (R334W,
%), p.Ala561Glu (A561E, 2.9%), p.Gly85Glu (G85E, 1.8%),
.Arg1066Cys (R1066C) and c.3272-26A>G (1.3% each),
.Gln1100Pro (Q1100P, 0.8%) and p.Pro205Ser (P205S, 0.7%),
ave been reported in CF Portuguese patients, presenting
igher frequencies than expected and suggesting that they
ight be specific to the Portuguese population.2,14 Addi-
ionally, previous studies carried out in a cohort of infertile
ortuguese patients with congenital bilateral absence of the
as deferens (CBAVD) showed a very heterogeneous CFTR
anel.15
In addition to CF, CFTR variants are also responsible for
ther diseases, usually monosymptomatic and classified as
FTR-related disorders (RD).16 Many of these patients may
arry a CF-pathogenic variant on one allele and a likely
athogenic variant on the other allele, or even in both
lleles.
Commercial kits developed for CF screening test only a
imited number of common CF-causing variants and there-
ore may miss sequence variants that can be responsible
or less severe CFTR-RDs phenotypes. The development
f molecular biology techniques such as next-generation
equencing (NGS), made possible a complete analysis of the
A
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FTR gene in a way that is less labour-intensive and less
xpensive than the traditional Sanger sequencing.
In Portugal, the spectrum of CFTR sequence variants
re not established. The preliminary results of the pilot
tudy for CF newborn screening in Portugal which started in
ctober 2013, estimates a substitutte by: 1:7500 frequency
f CF (unpublished data). The recent implementation of a
ational CF registry centre and the different approaches
sed for genetic testing carried out by the different labo-
atories has up to now made the calculation of frequencies
f CFTR variants unsafe.
The present work reports the spectrum of CFTR variants
n a sample from northern Portugal.
aterial and methods
election of individuals
his study is based on a Portuguese population-based birth
ohort study -- Generation XXI.17 Participants were recruited
t level III public units providing obstetrical and neonatal
are in the metropolitan area of Porto, Portugal, between
pril 2005 and August 2006. The baseline sample comprised
647 participants. At 4 years of age, the total cohort was
nvited to a re-evaluation that occurred between April 2009
nd July 2011.
To fit into the general study aim, only children with
arents of Portuguese nationality were included. For this
pecific study, 512 participants were randomly selected at
he 4 years old follow-up. For each child, a sample from
uccal mucosa cells was collected with a swab.
Genomic DNA was extracted from buccal mucosa cells,
sing a commercial kit (JETQUICK, Genomed). DNA samples
ere then banked in the Genetics Service of the Faculty of
edicine, University of Porto.
FTR gene sequencing
n total 512 DNA samples were completely sequenced and
nalyzed. CFTR gene sequencing of the first 206 samples
as performed by Sanger sequencing. For that purpose
olymerase chain reaction of the 27 CFTR exons and their
anking intronic regions was performed. The amplified frag-
ents were then sequenced and analyzed to identify DNA
equence variants.
Due to the update of the molecular techniques, the
emaining 306 samples were analyzed by NGS (Ion Torrent
GM). Assay design was performed in order include the 27
FTR exons, 50 bp into flanking introns and untranslated
egions.
The annotation of CFTR sequence variants was based on
he GenBank cDNA reference sequence NM 000492 and in
ccordance to the standard nomenclature recommended by
he Human Genome Variation Society.
linical characterizationfter molecular analysis and according to what was stated by
hildren’s parents in the specific informed consent, results
f the genetic analysis were communicated to the parents.
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Genetic counselling was offered to all parents and children
with at least one pathogenic or likely pathogenic variant.
Parents were studied to ascertain the origin of the variant
and to validate compound heterozygosity in children with
two pathogenic or likely pathogenic variants. Clinical evalu-
ation of these children was performed in collaboration with
Genetics Consultation of São João Hospital Centre (CHSJ).
This clinical characterization included: (1) family history;
(2) evaluation of clinical symptoms of CF, including stature-
ponderal growth and pancreatic and pulmonary disease;
(3) quantitative sweat chloride test (positive sweat
test > 60mmol/L). Asthma diagnosis was based on the child
current and past medical history, family history, physical
examination and laboratory tests (prick test).
Ethics
All the procedures were explained to the participants and
written informed consent forms were signed in every phase
of Generation XXI, by parents or the child’s legal guardian,
according to the Ethical Principles for Medical Research
Involving Human Subjects expressed in the Declaration of
Helsinki. Also, for this particular study, a specific informed
consent form was signed by the parents of the child.
The study was approved by the University of Porto Medi-
cal School/CHSJ Ethics Committee and by the Portuguese
Data Protection Authority.
Results
In total, 512 DNA samples were completely sequenced
and analyzed. A total of 73 different CFTR sequence vari-
ants were identified. From these DNA variants, 30 included
molecular variants that had been previously reported as CF-
pathogenic, CFTR-RD or likely pathogenic variants (Table 1)
and 43 are benign.
From the forty-three benign variants, 42 were already
included in the CFTR mutation database9 and one, the
c.1614T>C (p.Asn538Asn) in the exon 12, was identified for
the first time in one allele. The c.1614T>C substitution does
not alter the codified amino acid nor any significant splic-
ing motif; it is predicted to be a neutral variant by the
PROVEAN18 and Human Splicing Finder19 software tools.
Taking into account the 30 CFTR variants already reported
as CF or CFTR-RD pathogenic variants, a total of 123
sequence variants alleles were detected. From the 512 chil-
dren studied, 92 were found to be carriers of one variant
(92/512, 18.0%; 95%CI: 14.7--21.6) and 8 children had two
variants (8/512, 1.6%; 95%CI: 0.7--3.1) (Table 2).
However, the majority of these CFTR variants have
been reported in patients with a less severe CFTR-
RD phenotype. Thus, considering only DNA sequence
variants classified as CF-pathogenic (p.Phe508del,
p.Arg1162X and p.Phe1257Leu) or variants that in
association with a pathogenic variant may cause CF
(p.Leu633Ile, p.Tyr1014Cys, p.Phe1052Val, p.Gly1069Arg
and p.Met1407Thr), the CF carrier frequency decreases
to 3.3% (95%CI: 1.9--5.3) (17/512) or even to 1.4% (95%CI:
0.06--2.5) (7/512), if only the 3 CF-pathogenic variants are
considered.20--23
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Out of a total of 30 CFTR variants, 8 children
ere identified with two variants (8/512, 1.6%; 95%CI:
.7--3.1). However, when only CF-pathogenic or likely
athogenic variants were considered, only one child
p.Phe508del/p.Phe1052Val) presented two CF-causing vari-
nts (1/512, 0.2%; 95%CI: 0.01--0.7) (Table 2).
The c.1210-12T[5] was the most frequent sequence vari-
nt, detected in 35 of the 1024 alleles analyzed (3.4%; 95%CI:
.4--4.6). It is associated with 11TGs repeats in 20 alleles,
2TGs in 11 alleles and 13TGs in 4 alleles (Table 1).
Beyond the c.1210-12T[5], the c.2002C>T (p.Arg668Cys)
as identified with an allelic frequency of 1.8% (95%CI:
.0--2.6), followed by the c.1727G>C (p.Gly576Ala) and the
.2260G>C (p.Val754Met) with allelic frequencies of 1.3%
95%CI: 0.7--2.0) and 0.8% (95%CI: 0.2--1.3), respectively
Table 1).
The CF-pathogenic variant, p.Phe508del, was identified
n 5 of the 1024 alleles (0.5%; 95%CI: 0.16--1.0) (Table 1).
Segregation analysis performed in the parents of the
hildren with two variants confirmed the compound het-
rozygosity.
Children with two sequence variants were evaluated for
he presence of clinical signs and symptoms of CF. Currently,
t 11 years of age, none of them had CF at the time of
linical evaluation, they presented normal stature-ponderal
rowth, had no respiratory symptoms, pancreatic insuffi-
iency or digestive disease history. Three children had a
uantitative sweat test value between 30 and 59mmol/L,
hile the other child had a value below 30mmol/L. The
hild identified with the p.Phe508del/p.Phe1052Val geno-
ype has a normal stature-ponderal growth, sweat test of
8mmol/L, pancreatic sufficiency and with the exception
f allergic asthma (prick test positive for mites), no other
ulmonary disease.
iscussion
n the present study, we analyzed the CFTR gene of 512 Por-
uguese children in order to estimate the spectrum of CFTR
ariants in this population.
In total, 73 different variants were identified in the CFTR
ene. From these variants, 42 have already been reported
s benign and 1, c.1614T>C (p.Asn538Asn), was detected
or the first in this study.9 This variant was also classified
s benign, based on the analysis of the protein change and
ioinformatics programmes.18,19
The remaining 30 variants included CF-pathogenic or
ikely pathogenic variants. The classification of these vari-
nts is difficult to establish due to in part to the lack of
enotype-phenotype correlation and the variability of dis-
ase expression in patients with a mild CF phenotype or
FTR-RDs.24
Based on previous studies and CF database, only
out of the 30 variants identified could be clas-
ified as CF-pathogenic, p.Phe508del, p.Arg1162X
nd p.Phe1257Leu.21,22 On the other hand the
.Leu633Ile, p.Tyr1014Cys, p.Phe1052Val, p.Gly1069Arg
nd p.Met1407Thr variants, have varying consequences and
ay cause CF when combined with another CF-pathogenic
ariant.20,23 Other sequence variants here detected do
ot cause CF, but have been associated with a less severe
6 A. Grangeia et al.
Table 1 CFTR sequence variants classified as pathogenic or likely pathogenic, found in the analyzed cohort of 512 Portuguese
children.
Exon/Intron cDNA change Protein change No. alleles Allelic freq. (%)
ex 2 c.91C>T p.Arg31Cys (R31C) 1 0.1
ex 3 c.224G>A p.Arg75Gln (R75Q) 2 0.2
ex 5 c.509G>A p.Arg170His (R170H) 1 0.1
ex 6 c.601G>A p.Val201Met (V201M) 1 0.1
ex 8 c.890G>A p.Arg297Gln (R297Q) 1 0.1
ex 8 c.1052C>G p.Thr351Ser (T351S) 2 0.2
ex9 c.1163C>T p.Thr388Met (T388M) 1 0.1
intron 9 c.1210-12[5T] (IVS8-5T) 35 3.4
c.1210--12[5T11TG] (IVS8-5T11TG) (20) (2.0)
c.1210--12[5T12TG] (IVS8-5T12TG) (11) (1.0)
c.1210--12[5T13TG] (IVS8-5T13TG) (4) (0.4)
ex 10 c.1327G>T p.Asp443Tyr (D443Y) 1 0.1
ex 11 c.1521 1523delCTT p.Phe508dela (F508del) 5 0.5
ex 12 c.1616T>C p.Ile539Thr (I539T) 1 0.1
ex 13 c.1684G>A p.Val562Ile (V562I) 3 0.3
ex 13 c.1727G>C p.Gly576Ala (G576A) 13 1.3
ex 14 c.1897C>A p.Leu633Ileb (L633I) 1 0.1
ex 14 c.2002C>T p.Arg668Cys (R668C) 18 1.8
ex 14 c.2173G>A p.Glu725Lys (E725K) 1 0.1
ex 14 c.2260G>C p.Val754Met (V754M) 8 0.8
ex 15 c.2502T>G p.Phe834Leu (F834L) 1 0.1
ex 17 c.2735C>T p.Ser912Leu (S912L) 1 0.1
ex 17 c.2855T>C p.Met952Thr (M952T) 1 0.1
ex 17 c.2900T>C p.Leu967Ser (L967S) 3 0.3
ex 19 c.2991G>C p.Leu997Phe (L997F) 5 0.5
ex 19 c.3041A>G p.Tyr1014Cysb (Y1014C) 2 0.2
ex 20 c.3154T>G p.Phe1052Valb (F12052V) 4 0.4
ex 20 c.3205G>A p.Gly1069Argb (G1069A) 2 0.2
ex 20 c.3322G>C p.Val1108Leu (V1108L) 1 0.1
ex 22 c.3484C>T p.Arg1162Xa (R1162X) 1 0.1
ex 22 c.3705T>G p.Ser1235Arg (S1235R) 5 0.5
ex 23 c.3771T>G p.Phe1257Leua (F1257L) 1 0.1
ex 26 c.4220T>C p.Met1407Thrb(M1407T) 1 0.1
123
a CF pathogenic variant.
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henotype or with CFTR-RDs. In these patients, although
he clinical symptoms are not expected to be severe
nough to meet the criteria of CF, they may present a
onosymptomatic disease that could appear later in life.
Compound heterozygotes patients for one of these vari-
nts with one CF-pathogenic variant may have a clinical
pectrum ranging from CBAVD to CF with sufficient pan-
reatic function. So, considering only the CF-pathogenic
ariants, p.Phe508del, p.Arg1162X and p.Phe1257Leu, the
F carrier frequency is 1.4% (7/512) and none of the children
ere found to simultaneously carry two CF-pathogenic vari-
nts. However, taking also into account the likely pathogenic
ariants, the carrier frequency increases to 17/512 (3.3%)
nd the prevalence of CF to 1/512 (0.2%). Although the car-
ier frequency is in accordance to what is expected and
o what has been reported in other countries, 3--4%, the
F prevalence observed was higher 1/512 (0.2%)2,5 (Ana
aracão, oral presentation, 2017). This higher prevalence
e
o
oCF pathogenic variant. The old terminology is within brackets ().
ould be explained by the fact that not all patients with
ikely pathogenic variants have CF and therefore this preva-
ence could have been overestimated. It is important to
ighlight that patients with a likely pathogenic variant, even
hen in compound heterozygosity with a CF-pathogenic
ariant may have a phenotype that ranges from CF to a
FTR-RD.
After clinical evaluation, the child with the
.Phe508del/p.Phe1052Val genotype does not fulfil the
riteria for CF diagnosis. However, since the likely
athogenic p.Phe1052Val variant has varying consequences
nd the clinical manifestations of CF can vary over the
ourse of a person’s lifetime, this patient would be
valuated periodically.The other children with two CFTR variants, although not
xpected to have CF, were also evaluated for the presence
f signs or symptoms related to a less severe CF phenotype
r to a CFTR-RD. None of them had CF.
Spectrum of CFTR gene sequence variants in a northern Portugal population 7
Table 2 CFTR gene sequence variants and clinical data in children with two pathogenic or likely pathogenic variants.
Patient code Protein/cDNA change Sweat test
(mmol/L)
Clinical data
Allele 1 Allele 2 Respiratory
symptoms
Gastrointestinal
disease
Others
1 -- Male p.Arg297Gln
(R297G)
p.Glu725Lys (E725K) Not available -- Pancreatic
sufficiency
Autism spectrum
disorder
2 -- Female p.Phe508dela
(F508del)
p.Ser912Leu (S912L) 32 -- Pancreatic
sufficiency
Tonsilittis
recurrents
3 -- Male p.Phe508dela
(F508del)
p.Leu967Ser (L967S) 40 -- Pancreatic
sufficiency
Tonsilittis
recurrents
4 -- Male p.Phe508dela
(F508del)
p.Phe1052Valb (F1052V) 48 Allergic asthma Pancreatic
sufficiency
--
5 -- Male p.Gly576Ala --
p.Arg668Cys
(G576A-R668C)
p.Leu997Phe (L997F) Not available -- Pancreatic
sufficiency
--
6 -- Male p.Met952Thr
(M952T)
c.1210--12[5T11TG]
(IVS8-5T11TG)
Not available -- Pancreatic
sufficiency
--
7 -- Female p.Leu967Ser
(L967S)
c.1210--12[5T12TG]
(IVS8-5T12TG)
26 Chronic
inflammatory
disease of the
airways
Pancreatic
sufficiency
--
8 -- Male p.Ser1235Arg
(S1235R)
c.1210--12[5T12TG]
(IVS8-5T12TG)
Not available Unknown Unknown Unknown
a CF pathogenic variant.
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Nevertheless, and according to the new Consensus Guide-
lines for Diagnosis of CF,25 these three children with a
quantitative chloride sweat test value between 30 and
59mmol/L, should perform another quantitative sweat test
in a different occasion and if the results are within the same
range they may have CF. In these cases, evaluation of CFTR
dysfunction could be assessed by nasal potential difference
or intestinal current measurement in order to confirm the
diagnosis of CF. However, in this cohort of children with no
CF clinical symptoms, it was not yet possible to do these
tests. The child with the p.Leu967Ser/c.1210--12T[5]TG[12]
genotype also presented asthmatic bronchitis, which may
be correlated with the CFTR variants. The child with the
p.Ser1235Arg/c.1210--12T[5]TG[12] is currently living out-
side Portugal and therefore could not be further analyzed.
Although the c.1210--12T[5]TG[12] in compound heterozy-
gosity with a pathogenic or likely pathogenic variant is
unlikely to cause disease, the c.1210--12T[5]TG[12] may
result in a mild form of CF or a CFTR-RD.13,26
The p.Glu725Lys and p.Ser912Leu, detected in two
children with other two variants have been reported
in combination with the c.1766+5G>A and p.Gly1244Val,
respectively, on the same chromosome.27,28 However, in
these children, the second variant in cis, c.1766+5G>A and
p.Gly1244Val, were not detected. Since the p.Glu725Lys
and p.Ser912Leu had been thought to be benign variants,
even in compound heterozygosity with p.Arg297Gln and
p.Phe508del, these children are not expected to meet
criteria for CF diagnosis. However, the presence of mild
symptoms or CFTR-RDs were evaluated in these children.
A
r
CCF pathogenic variant. The old terminology is within brackets ().
n fact, although no CF symptom was detected at present, 6
ut of the 8 children with two CFTR sequence variations are
oys and may have CBAVD. Additionally, apart from the clin-
cal characterization, genetic counselling was also offered
o these families.
These children were randomly selected from the north-
rn Portuguese population and so it would be expected that
he spectrum of CFTR variants detected during this work
ould represent the CFTR spectrum of the north of Portu-
al. The high percentage of likely pathogenic variants may
eflect a higher percentage of patients with milder forms of
F or CFTR-RDs. These patients are usually diagnosed only
n adolescence or adulthood and some of them are misdiag-
osed because the clinical manifestations differ from those
resent in classical CF. Due to the difficulty in establishing
he pathogenicity of some of the CFTR variants detected
uring the gene screening, the level of CFTR dysfunction
ould be confirmed by electrophysiological tests such as
asal potential difference measurement. Additionally, the
ajority of these variants are not included in the commer-
ial kits for CF screening. In fact, only the p.Phe508del and
he c.1210-12T[5], detected in the present study, would
ave been identified if commercial screening kits had been
sed. This highlights the limited power of detection of CFTR
ariants by commercial kits in heterogeneous populations
uch as the Portuguese population, compared to others in
hich a high detection level permits a quick genetic testing.
s a result, the complete analysis of the CFTR gene should be
ecommended for patients with clinical symptoms of classic
F with only one or no pathogenic variant detectable with
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1ommercial test kits and also for patients with clinical signs
f moderate CF or CFTR-RDs.
onclusions
ur data confirm previous studies that have shown that
he spectrum of CFTR variants varies according to the geo-
raphic and/or ethnic origin of each population, the highest
FTR allelic heterogeneity being detected in Mediterranean
ountries. More knowledge about the CFTR variants spec-
rum contributes to a more efficient genetic testing system
n the Portuguese population.
Additionally, it is important to compare these results with
ata obtained from the Neonatal CF Screening Programme,
n order to facilitate the early diagnosis of symptom-free-
ewborns carrying likely pathogenic variants.
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